Frank R. Oakes - 20 Jul 2023 Form 4/A - Amendment Insider Report for Edesa Biotech, Inc. (EDSA)

Reporting relationship: Director
Issuer ticker: EDSA
Reported as of: 20 Jul 2023
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 24 Jul 2023, 16:45:59 UTC
Original report date: 21 Jul 2023
Prior SEC filing: 07 Mar 2022
Source filing: View source filing
Reporting owner signature: /s/ Frank R. Oakes

Key filing fact

Frank R. Oakes filed Form 4/A - Amendment for Edesa Biotech, Inc. (EDSA) on 24 Jul 2023.

Key facts

This page summarizes Frank R. Oakes's Form 4/A - Amendment filing for Edesa Biotech, Inc. (EDSA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 24 Jul 2023, 16:45.

Change

Previous filing in this sequence was filed on 07 Mar 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EDSA transaction Derivative

Share Option (right to buy)

Award

Transaction value: $0
Shares: +20,000
Change %
Price: $0.000000
Shares after: 20,000
Date: 20 Jul 2023
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 20,000
Exercise price: $0.8277
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option vests monthly in equal proportions over 12 months beginning on the date of grant.

SEC remarks

This amendment on Form 4/A is being filed to amend the Form 4 filed on July 21, 2023, solely to correct an administrative error in the expiration date of the Share Option previously reported in Column 6 of Table II.